Ernst Berndt is the Louis E. Seley Professor in Applied Economics and a Professor of Applied Economics at the MIT Sloan School of Management.
He also is the co-director of the Biomedical Enterprise Program, a joint program of MIT Sloan and the Harvard-MIT Division of Health Sciences and Technology. Berndt also serves as director of the National Bureau of Economic Research Program on Technological Progress and Productivity Measurement.
His recent research focus has been on the changing dynamics of the healthcare industries. Berndt has examined how medical innovations have affected the costs of treating selected diseases over time, factors affecting the globalization of clinical trials (particularly in emerging economies), incentives to induce research and development into third-world diseases, how industry funding of the U.S. Food and Drug Administration through user fees has affected review times and safety withdrawal rates, and the impact of direct-to-consumer marketing of prescription pharmaceuticals on drug utilization. In other research, Berndt has assessed how illness and its treatment affect individuals’ ability to function at work. More generally, his research deals with assessing the sources of productivity growth and how productivity is measured. Berndt has implemented methods for adjusting prices for changes in quality in the pharmaceutical, healthcare, personal computer hardware, prepackaged software, and personal digit assistant product categories. He also has published research on the structure of the advertising services industries.
Berndt holds a BA in economics and philosophy from Valparaiso University, as well as an MS and a PhD from the University of Wisconsin.
Recent Posts by Ernst Berndt
Counting and identifying manufacturers able to supply the U.S. with generic drugs or their base ingredients is critical for promoting public health goals, yet the number and identity of these manufacturers is shrouded from public oversight. We recommend three measures that the U.S. Congress...
Soon after Sanofi Pharmaceuticals’ Inc. August 2012 launch of the biologic drug ziv-aflibercept (brand name Zaltrap) into the U.S. market, its price triggered an unusual act of defiance on the part of oncolAogists. Physicians from Memorial Sloan-Kettering Cancer Center stated in a New York...